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pH—Sensitive Mucoodhesive Film—Forming Gels 
Composition of Gel: 
- Molecule of interest 
-A solvent vehicle comprising at least 25% water 
A 'Wuter—insoluble swelluble mucoadhesive polymer(s) 
-pH—sensitive film—forming polymer(s) 
pH—Sensitive Muooodhesive Wax—Film Composites 
At 
components of A 
Composition of Wax—Film Composite: 
A“: pH-sensitive mucoadhesive loyer (comprised of the 
above less the solvent vehicle) 
B: Water—insoluble wox layer with water—soluble or water— 
swelloble polymer 
Note: Molecule of interest is contained in either A“ or B, or both 
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1 
PH-SENSITIVE MUCOADHESIVE 
FILM-FORMING GELS AND WAX-FILM 
COMPOSITES SUITABLE FOR TOPICAL 
AND MUCOSAL DELIVERY OF MOLECULES 
FIELD OF THE INVENTION 
The present invention relates to compositions and methods 
to treat the skin and mucosal surfaces with mucoadhesive 
?lm-forming gels and wax-?lm composites that are pH-sen 
sitive. The invention also relates to using such pH-sensitive 
?lm-forming gels and wax-?lm composites to deliver mol 
ecules of interest, namely active pharmaceuticals. The inven 
tion also relates to the use of said pH-sensitive ?lm-forming 
gels and wax-?lm composites to deliver molecules of interest, 
such as small molecules, peptides, proteins, and nucleic acids 
either locally to act at the site of administration or for the 
absorption of said molecules of interest across biological 
membranes into the systemic circulation. 
BACKGROUND OF THE INVENTION 
Pharmaceutical formulations intended to deliver drugs 
topically, either for local action at the site of administration or 
for absorption into the systemic circulation, have been 
described in the literature. These formulations are designed 
either for adherence of the dosage form to the skin (for dermal 
or transdermal delivery of drugs) or mucosal surface (for 
mucosal or transmucosal delivery of drugs). For skin delivery, 
formulations generally consist of dermal patches, pastes, 
band-aids, gels, lotions, sprays, or creams. For mucosal deliv 
ery, formulations generally consist of gels, creams, tablets, 
sprays, or ?lms. In either case, one speci?c requirement is that 
the dosage form remains at the administration site for a suf 
?cient amount of time so that the drug may function as 
needed. A second speci?c requirement is that the dosage form 
must consist of pharmaceutically acceptable materials. Many 
of the reported and commercially available delivery systems 
intended for topical and mucosal delivery are aqueous-based 
formulations comprising water-soluble excipients. However, 
these systems tend to be easily and quickly washed away from 
the application site within minutes after application. This is 
very undesirable if the drug must remain at the application 
site for a prolonged period in order to be ef?cacious. In an 
attempt to prolong the residence time at the application site, 
researchers have described the use of water-insoluble excipi 
ents in the formulations. However, most often the use of 
water-insoluble excipients necessitates the use of non-aque 
ous solvents to dissolve the excipients. Excessive and 
repeated administration of non-aqueous solvents is not desir 
able. 
Different types of formulations to deliver drugs topically 
are known in the art. Speci?c examples are illustrated below. 
US. Pat. No. 4,715,369 by Suzuki et al. relates to methods 
to treat the injured oral mucosa with a thin two-layer tablet 
comprised of both an adhesive layer and a nonadhesive layer. 
The adhesive layer is comprised of water-soluble cellulose 
based polymers and polyacrylic acid while the nonadhesive 
layer is comprised mostly of materials with no adhesive prop 
erties. The Suzuki patent does not teach the use of ?lm 
forming gels comprised of pH-sensitive polymers and water 
insoluble mucoadhesive polymers that form ?lms due to 
changes in pH and/or desolvation of the polymers. Further, 
the Suzuki patent does not teach the use of pH-sensitive 
wax-?lm composites intended to remain adhered to the skin 
or mucosal surface for a prolonged period of time. 
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US. Pat. No. 5,800,832 by Tapolsky et al. relates to a 
water-soluble, bioerodable device for the delivery of drugs, 
and speci?cally dyclonine, to mucosal surfaces. The device 
comprises an adhesive layer as well as a non-adhesive layer. 
Both the adhesive layer and the nonadhesive layer consist of 
water-soluble polymers such as cellulose-based polymers. 
The Tapolsky patent does not teach the use of ?lm-forming 
gels comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/or desolvation of the polymers. Further, the Tapolsky 
patent does not teach the use of pH-sensitive wax-?lm com 
posites intended to remain adhered to the skin or mucosal 
surface for a prolonged period of time. 
US. Pat. No. 5,955,097 by Tapolsky et al. relates to a non 
water-soluble gel, which adheres to mucosal surfaces and 
body tissues upon application and forms a ?lm. The gel com 
prises at least one water-insoluble cellulose-based polymer, a 
non-aqueous solvent, and at least one active pharmaceutical. 
The patent teaches that upon application to the mucosal sur 
face or skin, the non-aqueous solvent, primarily ethanol, 
evaporates, diffuses, or penetrates the surrounding tissue, 
resulting in precipitation of the non water-soluble polymers 
into ?lms. The Tapolsky patent further teaches the use of 50 to 
80% ethanol by weight in the pharmaceutical gel. The Tapol 
sky patent does not teach the use of ?lm-forming gels con 
taining at least 25% water by weight and comprised of pH 
sensitive polymers and water-insoluble mucoadhesive 
polymers that form ?lms due to changes in pH and/ or desol 
vation of the polymers. Further, the Tapolsky patent does not 
teach the use of pH-sensitive wax-?lm composites intended 
to remain adhered to the skin or mucosal surface for a pro 
longed period of time. 
US. Pat. No. 5,780,045 by McQuinn et al. relates to a 
transmucosal drug delivery device in the form of a sheet 
comprising an acid-containing particulate polymer dispersed 
in a polytetra?uoroethylene support matrix. The McQuinn 
patent does not teach the use of ?lm-forming gels comprised 
of pH-sensitive polymers and water-insoluble mucoadhesive 
polymers that form ?lms due to changes in pH and/ or desol 
vation of the polymers. Further, the McQuinn patent does not 
teach the use of pH-sensitive wax-?lm composites intended 
to remain adhered to the skin or mucosal surface for a pro 
longed period of time. 
US. Pat. No. 4,552,751 by Inaba et al. relates to the prepa 
ration of multi-layered ?lms of three, ?ve, or seven layers for 
the administration of speci?c prostaglandins to mucosal sites. 
The Inaba patent does not teach the use of ?lm-forming gels 
comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/ or desolvation of the polymers. Further, the Inaba patent 
does not teach the use of pH-sensitive wax-?lm composites 
intended to remain adhered to the skin or mucosal surface for 
a prolonged period of time. 
US. Pat. No. 4,517,173 by Kizawa et al. relates to a ?lm 
preparation consisting of at least three layers, including a 
pharmaceutical layer, a poorly water-soluble layer, and an 
intermediate layer. The pharmaceutical layer consists of pre 
donisolone and allantoin together with a water-soluble cellu 
lose-based polymer. The poorly water-soluble layer consists 
of shellack or fatty acids. The Kizawa patent does not teach 
the use of ?lm-forming gels comprised of pH-sensitive poly 
mers and water-insoluble mucoadhesive polymers that form 
?lms due to changes in pH and/or desolvation of the poly 
mers. Further, the Kizawa patent does not teach the use of 
pH-sensitive wax-?lm composites intended to remain 
adhered to the skin or mucosal surface for a prolonged period 
of time. 
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Us. Pat. No. 5,192,802 by Rencher describes the use of a 
bioadhesive teething gel comprising benzocaine, sodium car 
boxy methyl cellulose; an agent selected from the group 
consisting of xanthan gum and sodium alginate and a diluent 
selected from the group consisting of polyethylene glycol and 
polyethylene glycol with glycerine. U.S. Pat. No. 5,314,915 
by Rencher and Us. Pat. No. 5,298,258 by Akemi et al. also 
describe the use of aqueous or oil-based bioadhesive gelling 
agents. These patents do not teach the use of ?lm-forming 
gels comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/ or desolvation of the polymers. Further, these patents do 
not teach the use of pH-sensitive wax-?lm composites 
intended to remain adhered to the skin or mucosal surface for 
a prolonged period of time. 
U.S. Pat. Nos. 5,081,157 and 5,081,158 by PomerantZ 
relate to a ?lm-forming composition for topical application of 
medicaments to body tissues. The ?lm-forming composition 
includes hydroxypropyl cellulose, a volatile solvent, and an 
esteri?cation agent which reacts with the hydroxypropyl cel 
lulose to form a reaction product which is soluble in the 
solvent. These patents do not teach the use of ?lm-forming 
gels comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/ or desolvation of the polymers. Further, these patents do 
not teach the use of pH-sensitive wax-?lm composites 
intended to remain adhered to the skin or mucosal surface for 
a prolonged period of time. 
U.S. Pat. No. 4,900,554 by Yanagibashi et al. relate to the 
use of a device for the delivery of drugs in the oral cavity. The 
device comprises an adhesive layer consisting of at least one 
acrylic acid polymer, a water-insoluble cellulose derivative, 
and a pharmaceutical preparation, and a water-insoluble or 
sparingly soluble backing layer. Yanagibashi et al. state that 
“it is impossible to achieve an adhesive device for application 
to body tissue without all three components, that is, acrylic 
acid polymer, water insoluble cellulose derivative and water 
insoluble or sparingly soluble backing layer”. The 
Yanagibashi patent does not teach the use of ?lm-forming 
gels comprised of pH-sensitive polymers and water-insoluble 
mucoadhesive polymers that form ?lms due to changes in pH 
and/ or desolvation of the polymers. Further, the Yanagibashi 
patent does not teach the use of pH-sensitive wax-?lm com 
posites intended to remain adhered to the skin or mucosal 
surface for a prolonged period of time. 
As illustrated, the references described above appear to 
lack preferred compositions and properties for an ef?cacious 
and pharmaceutically acceptable bioadhesive delivery sys 
tem. Namely, the references do not describe primarily aque 
ous-based ?lm-forming gels comprised of pH-sensitive poly 
mers and water-insoluble mucoadhesive polymers that form 
?lms due to changes in pH and/or desolvation of the poly 
mers. Further, the references do not describe pH-sensitive 
mucoadhesive wax-?lm composites intended to remain 
adhered to the skin or mucosal surface for a prolonged period 
of time. 
SUMMARY OF THE INVENTION 
The invention is directed to a pharmaceutical gel compo 
sition comprising: 
a solvent vehicle, 
at least one water-insoluble swellable mucoadhesive poly 
mer, 
at least one pH-sensitive ?lm-forming polymer, and 
at least one molecule of interest. 
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The solvent vehicle may be comprised of at least 25 to 100 
parts water or buffered water with 0 to 75 parts of ethanol, 
propylene glycol, glycerin, polyethylene glycol, or combina 
tions thereof. The water-insoluble swellable mucoadhesive 
polymer may be polyacrylic acid cross-linked with polyalk 
enyl ether or divinyl glycol, wherein the water-insoluble 
swellable mucoadhesive polymer is preferably, NOVEON or 
CARBOMER. The water-insoluble swellable mucoadhesive 
polymer may be present at a concentration of from 0.1% to 
20% by weight. 
The pH-sensitive polymer is a copolymer of methacrylic 
acid and acrylic or methacrylic ester. Preferably, it is present 
at a concentration of from 0.05% to 10% by weight. More 
preferably, the polymer is a Eudragit polymer, or a chemical 
derivative thereof. 
The molecule of interest may comprise an active pharma 
ceutical such as an antimicrobial, antiviral, antiin?ammatory, 
antiseptic, antihistamine, a local anesthetic, a disinfectant, a 
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a 
sweetener, a ?avoring agent, a diagnostic agent, or combina 
tion thereof. Preferably, the molecule of interest is amlex 
anox, triclosan, peptide, protein, hirudin, plasmid DNA, 
lidocaine, benzocaine, dyclonine, or benzodiazepine drug or 
a derivative thereof. 
The invention is also directed to a pharmaceutical gel 
which when applied to the skin or mucosal surface forms a 
?lm, said gel comprising a solvent vehicle, at least one water 
insoluble swellable mucoadhesive polymer, at least one pH 
sensitive ?lm-forming polymer, and at least one molecule of 
interest, wherein said ?lm is formed due to changes in pH and 
desolvation of the polymer, and wherein said ?lm provides 
for the delivery of the molecule of interest to or through the 
application site. The solvent vehicle may be comprised of at 
least 25 to 100 parts water with 0 to 75 parts of ethanol, 
propylene glycol, glycerin, polyethylene glycol, or combina 
tions thereof. The water-insoluble swellable mucoadhesive 
polymer may be polyacrylic acid cross-linked with polyalk 
enyl ether or divinyl glycol. Preferably, the water-insoluble 
swellable mucoadhesive polymer is NOVEON or CAR 
BOMER. The water-insoluble swellable mucoadhesive poly 
mer may be present at a concentration of from 0.1% to 20% by 
weight. 
The pH-sensitive polymer may be a copolymer of meth 
acrylic acid and acrylic or methacrylic ester. Preferably, it is 
present at a concentration of from 0.05% to 10% by weight. 
More preferably, the polymer is a Eudragit polymer, or a 
chemical derivative thereof. 
The molecule of interest may comprise an active pharma 
ceutical such as an antimicrobial, antiviral, antiin?ammatory, 
antiseptic, antihistamine, a local anesthetic, a disinfectant, a 
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a 
sweetener, a ?avoring agent, a diagnostic agent, or combina 
tion thereof. Preferably, the molecule of interest is amlex 
anox, triclosan, peptide, protein, hirudin, plasmid DNA, 
lidocaine, benzocaine, dyclonine, or benzodiazepine drug or 
a derivative thereof. The application site may be the skin, 
mouth, vagina, nose, nasal cavity, or other accessible mucosal 
site. 
The invention is also directed to a wax-?lm composite 
comprised of a pH-sensitive mucoadhesive layer and a water 
insoluble wax layer. The pH-sensitive mucoadhesive layer 
may be present at a concentration of 20% to 90% by weight, 
and the water-insoluble wax layer may be present at a con 
centration of 10% to 80% by weight. The pH-sensitive 
mucoadhesive water-insoluble layer may be comprised of: 
at least one water-insoluble swellable mucoadhesive poly 
mer, 
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at least one pH-sensitive ?lm-forming polymer, and 
at least one molecule of interest. 
The water-insoluble swellable mucoadhesive polymer 
may be polyacrylic acid cross-linked with polyalkenyl ether 
or divinyl glycol. Preferably, the water-insoluble swellable 
mucoadhesive polymer is NOVEON or CARBOMER. The 
water-insoluble swellable mucoadhesive polymer may be 
present at a concentration of from 0.1% to 20% by weight. 
The pH-sensitive polymer may be a copolymer of meth 
acrylic acid and acrylic or methacrylic ester. Preferably, it is 
present at a concentration of from 0.05% to 10% by weight. 
More preferably, the polymer is a Eudragit polymer, or a 
chemical derivative thereof. 
The molecule of interest may comprise an active pharma 
ceutical such as an antimicrobial, antiviral, antiin?ammatory, 
antiseptic, antihistamine, a local anesthetic, a disinfectant, a 
keratolytic, an analgesic, an anti-migraine, an anti-fungal, a 
sweetener, a ?avoring agent, a diagnostic agent, or combina 
tion thereof. Preferably, the molecule of interest is amlex 
anox, triclosan, hirudin, plasmid DNA, lidocaine, ben 
zocaine, dyclonine, or benzodiazepine drug or a derivative 
thereof. The wax-?lm composite may comprise at least one 
water-insoluble pharmaceutical wax having a melting point 
between 40° C. and 100° C. and at least one water-soluble or 
water-swellable polymer. 
The wax may be DENTSPLY® Utility Wax (Dentsply 
Prosthetics, York, Pa.), beeswax, emulsifying wax, microc 
rystalline wax, carnauba wax, para?in wax, white wax, yel 
low wax, or other suitable pharmaceutical wax. The water 
soluble or swellable polymer may be present in the insoluble 
wax layer at a concentration of 0.05 to 10% by weight. The 
water-soluble or swellable polymer may be tragacanth, poly 
vinyl pyrrolidone, polyvinyl alcohol, cross-linked poly 
acrylic acid, polyethylene glycol, a cellulose polymer deriva 
tive, or other suitable pharmaceutical polymer that is water 
soluble or water-swellable. In the wax-?lm composite, the 
molecule of interest may be contained in and released from 
either the pH-sensitive mucoadhesive layer or the water-in 
soluble wax layer. 
The molecule of interest comprises an active pharmaceu 
tical compound such as an antimicrobial, antiviral, antiin 
?ammatory, antiseptic, antihistamine, a local anesthetic, a 
disinfectant, a keratolytic, an analgesic, an anti-migraine, an 
anti-fungal, a sweetener, a ?avoring agent, a diagnostic agent, 
or a combination thereof. The molecule of interest may com 
prise an active pharmaceutical such as an antimicrobial, anti 
viral, antiin?ammatory, antiseptic, antihistamine, a local 
anesthetic, a disinfectant, a keratolytic, an analgesic, an anti 
migraine, an anti-fungal, a sweetener, a ?avoring agent, a 
diagnostic agent, or combination thereof. Preferably, the mol 
ecule of interest is amlexanox, triclosan, protein, peptide, 
hirudin, plasmid DNA, lidocaine, benzocaine, dyclonine, or 
benzodiazepine drug or a derivative thereof. Preferably, the 
hirudin may be complexed with a substance of opposite 
charge. More preferably, the substance of opposite charge 
may be chitosan or protamine. Alternatively, the molecule of 
interest may be a plasmid DNA or plasmid DNA complexed 
with a substance of opposite charge such as chitosan, prota 
mine, or a cationic lipid. 
The application site for the wax-?lm composite may be the 
skin, mouth, vagina, nasal cavity, or other accessible mucosal 
site. Preferably, the wax-?lm composite adheres to the appli 
cation site for at least 1 hour. Preferably, the wax-?lm com 
posite has a total thickness of less than 5 mm. 
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The invention is also directed to a method of making the 
above pharmaceutical gel composition, comprising: 
(i) adding a mucoadhesive polymer to a stirring water to 
form a solution that is clear and viscous, 
(ii) adding the pH-sensitive ?lm-forming polymer to the 
solution formed in step (i) and measuring the pH of the 
solution, 
(iii) adding the molecule of interest to the solution of step 
(ii), and 
(iv) forming the ?nal gel composition. 
The invention is also directed to a method of making the 
above wax-?lm composite, comprising: 
(i) forming a homogeneous mucoadhesive ?lm by fusing a 
mucoadhesive polymer and a pH-sensitive ?lm-forming 
polymer, 
(ii) homogeneously coating one side of the mucoadhesive 
?lm of step (i) with a melted wax composition, and 
(iii) drying the wax composition to form the wax-?lm 
composite, wherein the molecule of interest is added in 
either step (i) or (ii), or the molecule of interest is added 
to the mucoadhesive side after the wax-?lm composite is 
formed. 
Furthermore, the invention is also directed to a method of 
treating a disease or an illness by administering to a person in 
need thereof, the gel or the wax-?lm composite as described 
above comprising a molecule of interest. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention will become more fully understood 
from the detailed description given hereinbelow, and the 
accompanying drawings which are given by way of illustra 
tion only, and thus are not limitative of the present invention, 
and wherein; 
FIG. 1 shows a summary of the compositions of the inven 
tion 
FIG. 2 shows an in vitro adhesion time of 1A inch wax-?lm 
composites (n:3 each) on glass submerged in 40 mM 
KH2PO4/NaOH buffer, pH 6 at 37° C. (unstirred). Each 
mucoadhesive layer contains 5.0i5.3 mg of total polymer 
comprised of NOVEON and EUDRAGIT S100 in the ratios 
indicated. The wax layer consists of DENTSPLY® Utility 
Wax containing 1% w/w tragacanth polymer. *Indicates that 
different volumes of mucoadhesive gels were cast as 
described in Example 8. See Table 1 and Example 8 for 
additional details. 
FIG. 3 shows in vitro adhesion time of 1A inch wax-?lm 
composites (n:3 each) on glass submerged in 40 mM 
KH2PO4/NaOH buffer, pH 6 at 37° C. (stirred at 100 rpms). 
Each mucoadhesive layer contains from 1.2 mg to 11.2 mg of 
total polymer comprised of NOVEON and EUDRAGIT S100 
in a weight ratio of 3:1. The wax layer consists of 
DENTSPLY® Utility Wax containing 1% w/w tragacanth 
polymer. See Table 2 and Example 9 for additional details. 
FIG. 4 shows in vitro adhesion time of 1A inch wax-?lm 
composites containing plasmid DNA (10 pg) either incorpo 
rated during the manufacturing process (‘preload’) or ali 
quoted onto the mucoadhesive layer after the manufacturing 
process (‘postload’). Wax-?lm composites (n:5 each) were 
adhered to glass and submerged in 40 mM KHZPO4/NaOH 
buffer, pH 6 at 37° C. (unstirred). See Example 10 for addi 
tional details. 
FIG. 5 shows a standard curve forplasmid DNA in solution 
as measured by the PicoGreen DNA Quantitation Kit (from 
Molecular Probes, Inc., Eugene, Oreg.). 
FIG. 6 shows the release of plasmid DNA pre-loaded into 
wax-?lm composites. Wax-?lm composites were made as 
US 7,803,392 B2 
7 
described in Example 10 using a mucoadhesive gel com 
prised of NOVEON/EUDRAGIT S100 (3:1 w/w) and plas 
mid DNA. The wax layer consists of DENTSPLY® Utility 
Wax containing 1% w/w tragacanth polymer. Five 1A inch 
wax-?lm composites containing of plasmid DNA (5 pg) were 
submerged separately into 1 mL 10 mM PBS buffer, pH 7.4 at 
37° C. At various times, exactly 100 uL solution was ali 
quoted for DNA quantitation using the PicoGreen DNA 
Quantitation Kit. Exactly 100 uL fresh PBS was added to 
replace the removed volume at each time point. 
FIG. 7 shows the release of plasmid DNA post-loaded into 
wax-?lm composites. Wax-?lm composites were made as 
described in Example 10 using a mucoadhesive gel com 
prised of NOVEON/EUDRAGIT S100 (3:1 w/w). The wax 
layer consists of DENTSPLY® Utility Wax containing 1% 
w/w tragacanth polymer. Plasmid DNA (5 pg) was added to 
?ve individual 1A inch wax-?lm composites, allowed to air 
dry for 4 hours, and then submerged separately into 1 mL 10 
mM PBS buffer, pH 7.4 at 370 C. At various times, exactly 
100 uL solution was aliquoted for DNA quantitationusing the 
PicoGreen DNA Quantitation Kit. Exactly 100 uL fresh PBS 
was added to replace the removed volume at each time point. 
FIG. 8 shows: (A) The reaction kinetics of Chromozym 
TH and uncomplexed thrombin. Hirudin was added to excess 
thrombin and residual uncomplexed thrombin was assayed 
spectroscopically after the addition of Chromozym-TH. 
Hirudin was added to the 1.0 ml volume in the following 
amounts: 0 ng (III), 16.9 ng (C), 33.8 ng (A), 50.7 ng (A), 67.6 
ng (o), and 84.4 ng (I). (B) Calibration curve for released 
hirudin in solution. The ?gure was made by plotting the 
difference between the thrombin base value absorbance 
(thrombin in the presence of substrate only) and the hirudin 
sample values versus the concentration of hirudin standards 
from A. 
FIG. 9 shows an HPLC Standard Curve for Hirudin. Three 
standard curves for hirudin were generated using a C18 
Nucleosil® 5 pm analytical column (4.6><250 mm). The 
mobile phase consisted of water:acetonitrile:tri?uoroacetic 
acid (59.95:40:0.05 w/w/w). The ?ow rate was 0.6 mL/min. 
Each 50 uL sample of each standard curve was injected three 
times and the average AUC was plotted. 
FIG. 10 shows the Particle Size of Hirudin/Chitosan Com 
plexes in water made with hirudin at a Concentration of 0.5 
mg/mL. 
FIG. 11 shows the Zeta Potential of Hirudin/Chitosan 
Complexes in water made with Hirudin at a Concentration of 
0.1 mg/mL. Zeta Potential values are reported as the mean 
and standard deviation of three measurements. 
FIG. 12 shows the stability of Hirudin/Chitosan Com 
plexes (4:1 w/w) made in water as function of Hirudin con 
centration and storage time. All samples were stored at 4° C. 
For the Day 7 sample analysis, exactly 100 uL of Hirudin/ 
Chitosan complexes in water was diluted in 900 uL ethanol to 
determine the stability of the complexes in ethanol. 
DETAILED DESCRIPTION OF THE INVENTION 
The invention relates to delivery systems suitable for the 
topical and mucosal delivery of molecules of interest. Spe 
ci?cally, the invention relates to; 1) compositions of pH 
sensitive mucoadhesive ?lm-forming gels, 2) uses of pH 
sensitive mucoadhesive ?lm-forming gels, 3) compositions 
of pH-sensitive mucoadhesive wax-?lm composites, and 4) 
uses of pH-sensitive mucoadhesive wax-?lm composites. A 
summary of the compositions of the invention is shown in 
FIG. 1. 
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The pH-sensitive mucoadhesive ?lm-forming gel is a phar 
maceutical gel which when applied to the skin or mucosal 
surface forms a ?lm, said gel comprising a solvent vehicle, at 
least one water-insoluble swellable mucoadhesive polymer, 
at least one pH-sensitive ?lm-forming polymer, and at least 
one molecule of interest, said ?lm forming due to changes in 
pH and desolvation of the polymer, said ?lm providing for the 
delivery of the molecule of interest to or through the applica 
tion site. 
The pH-sensitive mucoadhesive wax-?lm composite is a 
bi-layer pharmaceutical ?lm less than 5 mm in diameter that 
when applied to the skin or mucosal surface adheres to the 
application for at least 1 hour. The wax-?lm composite is 
comprised of a pH-sensitive mucoadhesive layer and a water 
insoluble wax layer. 
De?nitions and Preferred Embodiments 
As used herein, certain terms may have the following 
de?ned meanings. 
As used in the speci?cations and claims, the singular form 
a, an and the include plural references unless the context 
clearly dictates otherwise. For example, the term a pharma 
ceutical may refer to one or more pharmaceuticals for use in 
the presently disclosed formulations and methods. 
The term molecule of interest is de?ned as any synthetic or 
naturally occurring substance including elements, radioac 
tive elements, synthetic or natural small molecules, peptides, 
proteins, nucleic acids, or any combinations thereof. 
The term active pharmaceutical means any synthetic or 
naturally occurring substance including elements, radioac 
tive elements, synthetic or natural small molecules, peptides, 
proteins, nucleic acids, or any combinations thereof intended 
to be administered to a warm-blooded mammal to elicit a 
pharmacological response. The terms pharmaceutical, active 
pharmaceutical, and drug as used herein are identical in 
meaning and thus are used interchangeably. It is preferred that 
the active pharmaceutical be an anti-microbial, antiviral, anti 
in?ammatory, antiseptic, antihistamine, tranquilizer, seda 
tive, anti-nausea, local anesthetic, disinfectant, keratolytic, 
analgesics including anti-migraine, anti-fungal, sweetener, 
?avoring agent, diagnostic agent, peptide, protein, antigen, 
monoclonal antibody, polyclonal antibody, nucleic acid, or 
combinations thereof. More preferably, the active pharma 
ceutical is amlexanox, triclosan, lidocaine, dyclonine, ben 
zocaine, a benzodiazepine, hirudin, antisense oligonucle 
otide, or plasmid DNA, or any derivative or combinations 
thereof. 
Amlexanox: The chemical name of Amlexanox is 
2-amino-7-(1-methylethyl)-5-oxo-5H-[1]benzopyrano-[2,3 
b]-pyridine-3-carboxylic acid. Amlexanox is the active ingre 
dient in the commercial product, Aphthasol, which acceler 
ates the healing of aphthous ulcers in the mouth by an 
unknown mechanism (Binnie et al. 1997; Khandwala et al. 
1997a; Khandwala et al. 1997b). The Aphthasol product is a 
5% paste. In cell culture experiments, Amlexanox has been 
shown to inhibit the formation or release of in?ammatory 
mediators such as histamine and leukotrienes from mast cells, 
neutrophils, and mononuclear cells (Urisu et al. 1990). Eur 
ther, in animals, Amlexanox has anti-allergic and anti-in?am 
matory properties and has been shown to inhibit both imme 
diate and delayed hypersensitivity reactions (Saijo et al. 
1985; Saijo et al. 1986). Amlexanox has very poor solubility 
in ethanol (0.58 mg/mL) and water (0.005 mg/mL). However, 
the solubility of Amlexanox increases with pH. 
Triclosan: The chemical name of Triclosan is 2,4,4' 
Trichloro 2'-hydroxy-diphenyl-ether 5-chloro 2-(2,4-dichlo 
rophenoxy)-phenol. Triclosan is a broad-spectrum antibacte 
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rial that has activity against a wide range of gram-positive and 
gram-negative bacteria (Zuckerbraun et al. 1998). Triclosan 
has been shown to inhibit bacterial fatty acid synthesis at the 
enoyl-acyl carrier protein reductase (Fabl) step (Heath et al. 
1999). It has gained wide-spread use as antibacterial agent 
that is used in toothpastes, kitchen utensils and toys. Triclosan 
has also been formulated in mouthwashes (Mandel 1994) and 
liposomes (Jones et al. 1993). Triclosan has a pKa of7.9 and 
is insoluble in water, except in alkaline solutions where it is 
readily soluble (Loftsson et al. 1999). However, triclosan is 
soluble in ethanol and polyethylene glycol 400 and many 
other organic solvents. 
Hirudin: Hirudin is the most potent and speci?c known 
inhibitor of thrombin (KZ:0.2 pM) (Markwardt 1989; Mark 
wardt 1991a; Markwardt 1991b; Fenton et al. 1991). Hirudin 
was originally isolated from medicinal leeches (Hirudo 
medicinalis), but is now available in large quantities due to 
recombinant techniques (Riehl-Bellon et al. 1989). Unlike 
heparin, hirudin does not require endogenous cofactors to 
function and does not have associated bleeding complica 
tions. Hirudin is a relatively small 65 amino acidpeptide (Mw 
7000) with remarkable stability over a broad range of pH (pH 
3*10), temperature (i.e., up to 60° C.), and solvent conditions 
(Chang 1991; Eric and Caroline 1991). The main structure of 
hirudin is characterized by an apolar disul?de knot with a 
very anionic (negatively-charged) tail. The apolar knot of 
hirudin masks the catalytic site of thrombin by interacting 
with its apolar site (i.e., via hydrophobic interaction). The 
anionic tail of hirudin (18 amino acids) interacts with the 
anion-binding exosite of thrombin. It is the combination of 
the apolar binding and the anion-binding that accounts for the 
very high af?nity of hirudin and thrombin. The presence of 
the apolar knot and anionic tail on hirudin results in both 
hydrophobic and hydrophilic surface interactions. For 
example, in solution, hirudin forms micellar complexes (e.g., 
tetramers) with itself. Further, the apolar region of hirudin is 
known to interact with cell membranes while the anionic tail 
remains extracellular (Fenton 1989). It is likely that the 
anionic portion of hirudin is electrostatically repelled from 
the surface of cell membranes. Novartis Pharma obtained 
marketing approval in the European Union in 1998 for 
REVASC (desirudin; recombinant hirudin) for the prevention 
of deep-vein thrombosis following knee and hip replacement 
surgery. In clinical trials, patients receiving hirudin by sub 
cutaneous injection twice a day for 8 days had a nearly 30% 
lower overall rate of deep-vein thrombosis than those who 
received low molecular weight heparin (Eriksson et al 1997). 
Novartis is also performing clinical trials (Phase III) for the 
use hirudin in acute coronary syndrome. Several other indi 
cations for hirudin are being pursued such as stasis-induced 
venous thrombosis, diffuse microthrombosis, and hemodi 
alysis (Markwardt 1989). Most of the potential applications 
of hirudin require blood levels between 80 to 3500 ng/mL 
(Markwardt 1989, Markwardt 1991). A potential problem 
with the use of injected forms of hirudin is that there are no 
effective antidotes for hirudin overdosing. If upon frequent 
injection, the wrong dose is given, there are no methods to 
turn the activity of hirudin off. For this reason alone, hirudin 
is a good candidate for transmucosal delivery via the buccal 
tissue. It is envisioned that the pH-sensitive mucoadhesive 
?lm-forming gel or wax-?lm composite containing hirudin, 
can easily be applied to the buccal tissue in the mouth and 
provide a means to safely control the dosing and dose sched 
uling of hirudin. 
Benzodiazepines: Benzodiazepines are among the most 
frequently prescribed drugs in the Western world. All benzo 
diazepine agonists exert similar pharmacodynamic actions 
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(e.g., activate central GABAergic neuroinhibition, thereby 
inducing anxiolysis, sedation/hypnosis, anticonvulsion and 
muscle relaxation. In turn, benzodiazepines are used for the 
treatment of seizures and insomnia, preoperative or proce 
dural sedation, and for the treatment of nausea and anxiety. 
Most if not all of the benzodiazepine bases have little or no 
solubility in water and are very lipophilic (Hjortkjaer et al. 
1999, Bechgaard et al. 1997). As a result, a great deal of 
research has gone into developing ef?cacious dosage forms 
of these drugs including; i) synthesizing water-soluble 
derivatives such as their hydrochloride salts, ii) developing 
injectable formulations of the benzodiazepine bases that do 
not result in precipitation of the drugs, and iii) exploring 
alternative routes of administration including intranasal, rec 
tal, and buccal. Previous work has shown that intranasal doses 
of the benzodiazepine bases dissolved in organic solvents 
lead to pharmacological responses with suitable pharmaco 
kinetic pro?les. However, the repeated use of organic solvents 
such as ethanol, polyethylene glycol, and propylene glycol 
for intranasal administration is not desirable. Alternatively, 
benzodiazepines have been given by buccal administration 
with very favorable results (Schwagmeier et al. 1998; Scott et 
al. 1999). For example, Schwagmeier et al. showed that the 
maximum plasma concentration of midazolam was 55.9 
ng/mL at 30 minutes following buccal administration of 5 mg 
midazolam with a mean bioavailability of 74.5%. Scott et al. 
reported that the buccal administration of 10 mg midazolam 
per 2 mL stopped 75% (30/40) seizures in children within an 
average time of 6 minutes after administration. Thus, buccal 
administration of benzodiazepines may be an attractive alter 
native to injection or intranasal administration. It is envi 
sioned that the said pH-sensitive mucoadhesive ?lm-forming 
gel or wax-?lm composite containing a benzodiazepine can 
easily be applied to the buccal tissue in the mouth and provide 
a means to safely and reproducibly deliver doses of the ben 
zodiazepines for the treatment of seizures and insomnia, pre 
operative or procedural sedation, and for the treatment of 
nausea and anxiety. Benzodiazepines suitable for delivery 
are, but not limited to, alprazolam, camazepam, clobazam, 
clonazepam, desmethyldiazepam, diazepam, ?unitrazepam, 
?urazepam, halazepam, lorazepam, lormethazepam, mida 
zolam, nitrazepam, oxazepam, pinazepam, prazepam, triaz 
olam, and derivatives and combinations thereof. 
The term pharmaceutically acceptable means that the sub 
stance is generally regarded to be safe when used in such a 
manner that is widely acceptable by those skilled in the art. 
For reference of acceptable materials, refer to THE UNITED 
STATES PHARMACOEPIA. 
The term pH-sensitive is de?ned as a substance that is 
affected by changes in pH so that the substance changes 
conformation, charge, solubility, or combinations thereof. A 
pH-sensitive polymer is de?ned as polymer that is affected by 
changes in pH so that the polymer changes conformation, 
charge, solubility, or combinations thereof. A pH-sensitive 
?lm-forming polymer is de?ned as polymer that is affected by 
changes in pH so that the polymer changes conformation, 
charge, solubility, or combinations thereof resulting in the 
precipitation, desolvation, or settling of the polymer into a 
?lm. For the purposes of this invention, it is preferred that the 
pH-sensitive ?lm-forming polymers have some solubility in 
aqueous-based vehicles above pH 5 but limited or no solubil 
ity below pH 5. It is more preferred that the pH-sensitive 
?lm-forming polymers have some solubility in aqueous 
based vehicles above pH 6 but limited or no solubility below 
pH 6. It is most preferred that the pH-sensitive ?lm-forming 
polymers have some solubility in aqueous-based vehicles 
above pH 7 but limited no solubility below pH 7. Examples of 
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pH-sensitive ?lm-forming polymers that meet these criteria 
are, but not limited to, Eudragits® and cellulose acetate 
phthalate polymers, or derivatives thereof. 
Eudragits® are synthetic cationic and anionic polymers of 
methacrylic acid and methacrylic acid esters in varying ratios. 
The polymers are generally regarded as safe and are included 
in the FDA Inactive Ingredients Guide (for oral capsules and 
tablets). The presence of positive charge (provided by the 
dimethylaminoethylmethacrylates), neutral charge (provided 
by the methacrylic acid esters) and negative charge (provided 
by the methacrylic acid) residues provides for interesting and 
useful solubility characteristics as a function of pH. In gen 
eral, the cationic Eudragits are soluble at lower pHs while the 
anionic Eudragits are soluble at higher pHs. Neutral 
Eudragits usually lack aqueous solubility at any pH. For the 
purposes of this invention, any Eudragit polymer or derivative 
thereof is preferred. Even more preferred is any anionic 
Eudragit or derivative thereof. Most preferred is Eudragit 
L100-55, Eudragit L100, and Eudragit S100 or derivatives 
thereof. Depending on the type of Eudragit polymer selected 
and its solubility as function of pH, ?lms having different 
properties can be prepared. Eudragit gels have been reported 
for the sustained-release of drugs via rectal administration 
(Goto et al. 1991; Kawata et al. 1991; Kim et al. 1992a; Kim 
et al. 1992b; Kim et al. 1992c; Umejima et al. 1993). Eudragit 
has also beenused in buccal patches (Wong et al. 1999). Wong 
et al. described the use of Eudragit patches with the water 
soluble cellulose-based polymers and swellable Carbopol 
polymers to deliver a model drug. However, for these studies 
Wong et al. utilized Eudragit NE40D, a neutral poly(ethy 
lacrylate methylmethacrylate) polymer that is insoluble at all 
pHs (non-pH-sensitive). Eudragit has also been used to ?lm 
coat tablets for pH-dependent colon targeting after oral deliv 
ery (Khan et al. 1999). Cationic Eudragit E, which is soluble 
at low pH, has also been proposed for the pH-controlled drug 
release from mini-tablets for the treatment of in?ammatory 
bowel disease (Leopold and Eikeler, 1998). No references or 
other prior art could be found that describe the use of mucoad 
hesive gels comprised of anionic polymers, that when applied 
to the skin or mucosal surfaces, form ?lms due to effect of pH 
on the solubility of the anionic polymers. 
Solubility refers to the extent to which a solute is dissolved 
in a solvent. Solubility can be described in terms such as 
described in REMINGTON’S PHARMACEUTICAL SCI 
ENCES 18th edition, 1990, ranging from very soluble (less 
than 1 part of solvent per 1 part of solute) to insoluble (more 
than 10,000 parts of solvent for 1 part of solute). The term 
water-insoluble refers to a substance or solute where more 
than 10,000 parts of water are needed to dissolve 1 part of 
solute. A water-insoluble swellable substance refers to a sub 
stance or solute that is water-insoluble but absorbs water and 
swells to form a colloidal dispersion. A colloidal dispersion, 
as de?ned by REMINGTON’S “consists of at least two dis 
crete phases”, namely a solid phase and a liquid phase. The 
term desolvation refers to phenomena whereby a solvent such 
as water diffuses from a swelled substance leaving primarily 
one solid phase comprised of the substance. A gel is de?ned 
as a semisolid consisting of particles interpenetrated by a 
liquid. A gel solution is de?ned as a gel which has a molecule 
of interest dissolved in solution in the liquid phase. A gel 
suspension is de?ned as a gel which has a molecule of interest 
suspended in the liquid phase. 
A wax refers to any water-insoluble substance composed 
of hydrocarbons, alcohols, fatty acids, and esters that are 
solids at temperatures below 40° C., but liquids at tempera 
tures of above 40° C. Suitable waxes are, but not limited to the 
following, DENTSPLY® Utility Wax, beeswax, emulsifying 
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wax, microcrystalline wax, camauba wax, paraffin wax, 
white wax, yellow wax, or other suitable pharmaceutical wax. 
It is preferred that the wax has a melting temperature between 
40° C. and 100° C., more preferred that the wax has a melting 
temperature between 40° C. and 80° C., and most preferred 
that the wax has a melting temperature between 40° C. and 
65° C. 
A wax-?lm composite refers to a bi-layer ?lm comprised of 
a pH-sensitive mucoadhesive layer and a water-insoluble wax 
layer. A molecule of interest may be loaded in and released 
from either the said pH-sensitive mucoadhesive layer or said 
water-insoluble wax layer. It is preferred that the molecule of 
interest is present in the wax-?lm composite at a concentra 
tion of 0.001% to 20% by weight, more preferably at a con 
centration of 0.001% to 10% by weight, and most preferably 
at a concentration of 0.001% to 5% by weight. It is preferred 
that the pH-sensitive mucoadhesive layer is present at a con 
centration in the wax-?lm composite of 20% to 90% by 
weight, more preferably at 30% to 80% by weight, and most 
preferably at 40% to 70% by weight. Preferably, the water 
insoluble wax layer is present at a concentration in the wax 
?lm composite of 10% to 80% by weight, more preferably at 
20% to 70% by weight, and most preferably at 30% to 60% by 
weight. For bonding the two layers of the bi-layer wax-?lm 
composite, it is preferred that the water-insoluble wax layer 
contain at least one water-soluble or water-swellable agents 
such as, but not limited to, tragacanth, polyvinyl pyrrolidone, 
polyvinyl alcohol, cross-linked polyacrylic acid, polyethyl 
ene glycol, a cellulose-based polymer or derivative thereof, a 
cross-linked polyacrylic acid polymer or derivative thereof, 
or other suitable pharmaceutical polymers that are water 
soluble or water-swellable. Preferably, the water-soluble or 
water-swellable agents are present in the wax layer at a con 
centration of 0.05% to 10% by weight, more preferably at 1% 
to 8% by weight, and most preferably at 1% to 5% by weight. 
It is envisioned that the wax-?lm composite may be applied to 
any readily accessible topical site including, but not limited to 
the following; any skin surface, rectal, vaginal, nasal cavity, 
any location in the mouth, or other accessible topical or 
mucosal surfaces. A dry wax-?lm composite will readily 
adhere to the surfaces described when the surfaces are wet 
with saliva or other bodily ?uids. However, for application to 
dry skin, it is envisioned that the dry wax-?lm composite 
could be easily wetted using tap water or another appropriate 
vehicle to promote subsequent adherence of the ?lm to the 
skin. It is preferred that the wax-?lm composite remain 
adhered to the application site for at least 1 hour, more pref 
erably for at least 75 minutes, and most preferably for at least 
90 minutes. 
The term mucoadhesive refers to a substance that sticks to 
or adheres to the skin or mucosal surfaces by forces that are 
measurable and by any number of mechanisms such as, but 
not limited to the following: hydrogen-bonding, ionic inter 
action, hydrophobic interaction, van der Waals interaction, or 
combinations thereof. 
Mucosal delivery is de?ned as the application of a formu 
lation or delivery system containing one or more active phar 
maceuticals to a mucosal site for the purpose of eliciting a 
pharmacological response at the site of application or alter 
natively, for the active pharmaceutical to be absorbed through 
the mucosal membrane into the systemic circulation. 
Mucosal sites applicable to the application of a formulation or 
delivery system are, but not limited to the following, vaginal, 
mouth, rectal, intranasal, and the eye. 
Transmucosal Delivery: Peptides, proteins, and other 
larger molecules are becoming increasingly more important 
as scientists search for new drugs to treat serious human 
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diseases. Most often, these new larger molecules have to be 
injected since bioavailability by other routes is low. However, 
developing injectable large molecule drugs is expensive and 
patient compliance is often low. Researchers in the ?eld of 
drug delivery have sought for decades for methods to dose 
larger molecules like peptides and proteins orally. However 
these drugs are prone to rapid and extensive degradation due 
to the low pH of the stomach as well as to peptidases and 
proteolytic enzymes throughout the gastrointestinal tract. 
Alternative routes have been sought such as transmucosal 
delivery via the lung, nose, and buccal tissue. The foreseen 
advantages of transmucosal delivery are; i) a faster onset of 
activity (i.e., achieve higher drug blood levels faster), ii) the 
avoidance of the ?rst hepatic pass metabolism and the related 
increase of bioavailability, and iii) the avoidance of side 
effects related to GI absorption (Rathbone et al. 1996). How 
ever, the barriers for effective transmucosal delivery (i.e., 
buccal delivery) are similar to those for oral delivery. For 
example, the oral mucosal tissue is also characterized by a 
mucous layer that lines the epithelia. The mucous layer pro 
vides a substantial physical barrier as well as a chemical 
barrier due to the presence of a multitude of peptidases and 
proteolytic enzymes. In theory, delivery systems designed to 
adhere to this mucous layer (i.e., mucoadhesives) can serve to 
protect peptides from rapid and/or extensive degradation 
(Bodde et al. 1990; Duchene et al. 1988; Harris and Robinson 
1990). The mechanism of mucoadhesion is complicated but is 
known to involve hydrogen bonding between the components 
of the delivery systems (i.e., polymers) and sialic acid resi 
dues of mucin (0.5i2.0% glycoprotein), the primary sub 
stance of mucous. The viscosity of the mucous layer is largely 
determined by the type and amount of the glycoproteins 
present. Usually, the mucous layer in the oral mucosa is about 
50(k600 pm thick and has a pH of 5.8i7.1. The combination 
of the mucous layer and the epithelial layer provides a sub 
stantial barrier for signi?cant drug absorption. This is espe 
cially true for peptide drugs that are prone to a high degree of 
proteolytic degradation in the mucous layer. Further, if the 
peptide drugs are anionic, the negatively-charged epithelial 
membrane below the mucous provides a repulsive electrical 
“fence” of sorts. 
In general, the oral transmucosal bioavailability of pep 
tides is low (<5%), but can be increased with the use of 
penetration enhancers designed to disrupt the mucosal and 
epithelial membranes (Sayani et al. 1993; Bhatt and Johnston, 
1996; Bayley et al. 1995; Bhatt and Johnston, 1997). The 
most often used types of penetration enhancers are surfac 
tants (i.e., sodium lauryl sulfate), bile salts (i.e., sodium 
deoxycholate), and fatty acids (i.e., oleic acid). Although 
these penetration enhancers typically increase the absorption 
of peptides, the safety and long term use of these agents is of 
concern. Further, these penetration enhancers, by design, do 
not function to speci?cally protect peptides from proteolytic 
degradation in the mucosal membrane. Alternatively, a plau 
sible strategy is to use more pharmaceutically acceptable 
excipients to physically protect peptides from rapid and 
extensive proteolytic degradation, rather than to rely on 
chemical means to disrupt biological membranes. For 
example, to enhance the transmuccosal delivery of nega 
tively-charged peptides, the peptides may be complexed with 
pharmaceutically acceptable excipients that have positive 
charges such as, but not limited to, chitosan, polylysine, or 
protamine. It is thought that complexation will serve two 
functions; i) decrease electrostatic repulsion of the peptide 
drugs with the negatively-charged epithelial membrane, and 
ii) decrease the extent of degradation of the peptide drugs by 
proteolytic enzymes in the mucosal membrane. 
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A complex refers to the physical interaction between two 
substances whereby a de?nite stoichiometry exists. Com 
plexation can occur by any number of mechanisms, includ 
ing, but not limited to: hydrogen-bonding, ionic interaction, 
hydrophobic interaction, van der Waals interaction, or com 
binations thereof. It is envisioned that molecules of interest 
formulated in said delivery systems may be complexed with 
various pharmaceutically acceptable agents to enhance their 
ef?cacy by any number of mechanisms described above, or 
those still unknown. 
Chitosan: Chitosan is a biodegradable polysaccharide 
composed of two subunits, D-glucosamine and N-acetyl-D 
glucosamine linked together by [3(1,4) glycosidic bonds. 
When dissolved in solution, the amino groups present in the 
glucosamine subunits (pKa 6.5) have a positive charge (Hen 
riksen et al. 1997; Schipper et al. 1996). Chitosan is known to 
be a mucoadhesive, and interacts ionically with the negatively 
charged sialic acid residues in mucin (Lehr et al. 1992). 
Chitosan has been used as a component of mucoadhesive 
systems (Takeuchi et al. 1996), as well as a controlled release 
and drug carrier systems (Berthold et al. 1993; Shiraishi et al. 
1993). Chitosan has also been found to increase the nasal 
absorption of insulin and calcitonin (Illum et al. 1994;Aspden 
et al. 1996), although the mechanism by which this occurs is 
not clear. Finally, chitosan has been reported to form com 
plexes with many negatively-charged molecules including 
indomethacin (Imai et al. 1991), sodium hyaluronate 
(Takayama et al. 1990), and pectin and acacia (Meshali et al. 
1993). One problem that may be encountered with the use of 
chitosan (100 kDa) is the poor solubility of 100 kDa chitosan 
at neutral pH. This lack of solubility may hinder its ability to 
form complexes with hirudin or our ability to study the com 
plex. A solution to this problem may be to obtain lower 
molecular weight chitosans (i.e., 10 kDa or 50 kDa). How 
ever, lower molecular weight chitosans are not commercially 
available. In our previous work with chitosan (MacLaughlin 
et al. 1998), we obtained lower molecular weight chitosans 
using a modi?ed depolymerization technique ?rst described 
by Peniston et al. (1975). This depolymerization process is a 
relatively simple deamination reaction where chitosan is 
chemically treated with sodium nitrite in 6% acetic acid at 25° 
C. for 1 hour. The amount of sodium nitrite used in the 
reaction determines the resulting chitosan molecular weight 
since the reaction is stoichiometric. For example, reacting 1 g 
of 100 kDa chitosan (Seacure 143) with 2% and 7% sodium 
nitrite results in ?nal chitosan molecular weights of 50 kDa 
and 10 kDa, respectively. The depolymerized chitosan poly 
mers are puri?ed and ready to use. The molecular weight of 
each depolymerized chitosan polymer is determined by gel 
chromatography through a Beckman Ultraspherogel 
SEC2000 column with a 1 mL/min ?ow-rate of eluent 0.1M 
acetic acid/sodium acetate buffer containing 0.05M sodium 
chloride as the mobile phase. 
Mucosal Vaccines: It is thought that the most effective 
vaccines for important viral and bacterial pathogens will 
require mucosal immunity since this is the site at which these 
pathogens infect the body (McGhee et al. 1992). However, all 
marketed vaccines except one (oral polio vaccine) are now 
administered by inj ectable routes and are ineffective at induc 
ing mucosal immunity. A new promising ?u vaccine (Flu 
mistTM from Aviron) is currently being tested in phase III 
clinical trials. FlumistTM is administered as a nasal spray. 
Since the nasal associated lymphoid tissue (NALT) is part of 
the mucosal network, this vaccine is the ?rst of potentially 
many new mucosal vaccines. Other mucosal routes are 
actively being pursued by researchers including the vaginal 
route and the mucosal regions of the gut (i.e., Peyer’s 









